[Effects of realgar on tissue factor expression of NB4 and MR2 cells].
OBJECTIVE
To investigate the effects of Realgar on procoagulant activity (PCA), tissue factor expression and tissue factor mRNA transcription in acute promyelocytic leukemia (APL) cell lines NB4 and MR2 cells.


METHODS
NB4 and MR2 cells were treated with 300 micrograms.L-1 Realgar PCA of the treated cells was detected using one-stage clotting assay. TF antigen was detected by ELISA and TFmRNA by semi-quantitive RT-PCR.


RESULTS
The PCA and TF antigen level in NB4 and MR2 cells were significantly higher than that in HL-60 and K562 cells. Realgar could down-regulate the membrane PCA, TF antigen and TF mRNA transcription of NB4 and MR2 cells in a time-dependent manner.


CONCLUSIONS
Down-regulating TF expression and PCA of NB4 and MR2 cells by Realgar may be one of the mechanism of its improvement effect on DIC-related hemorrhage of APL patients.
Zhao
Xiao-ai
XA
Department of Hematology, First Hospital, Xi'an Jiaotong University, Xi'an 710061, Shanxi, China. ZXA1112@163.com
Liu
Shan-xi
SX
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001152:Arsenicals / Q000494:pharmacology*; D001779:Blood Coagulation Factors; D003546:Cysteine Endopeptidases / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D015973:Gene Expression Regulation, Leukemic; D018922:HL-60 Cells; D006801:Humans; D020014:K562 Cells; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism* / Q000473:pathology; D008419:Materia Medica / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D013440:Sulfides / Q000494:pharmacology*; D013925:Thromboplastin / Q000096:biosynthesis* / Q000235:genetics; D014212:Tretinoin / Q000494:pharmacology
D000970:Antineoplastic Agents; D001152:Arsenicals; D001779:Blood Coagulation Factors; D008419:Materia Medica; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D013440:Sulfides; C058317:arsenic disulfide; D014212:Tretinoin; D013925:Thromboplastin; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant